CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis The Year in Cardiovascular Medicine 2020: Valvular Heart Disease: Discussing the Year in Cardiovascular Medicine for 2020 in the field of valvular heart disease is Professor Helmut Baumgartner and Dr Javier Bermejo. Mark Nicholls reports Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk Dapagliflozin for treating chronic heart failure with reduced ejection fraction Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week

Original Research2018 Jan 23. [Epub ahead of print]

JOURNAL:Catheter Cardiovasc Interv. Article Link

Prevalence, Presentation and Treatment of 'Balloon Undilatable' Chronic Total Occlusions: Insights from a Multicenter US Registry

Tajti P, Karmpaliotis D, Alaswad K et al. Keywords: chronic total occlusion; complex coronary intervention; percutaneous coronary intervention

ABSTRACT


Background - The prevalence, treatment and outcomes of balloon undilatable chronic total occlusions (CTOs) have received limited study.


Methods - We examined the prevalence, clinical and angiographic characteristics, and procedural outcomes of percutaneous coronary interventions (PCIs) for balloon undilatable CTOs in a contemporary multicenter US registry.


Results - Between 2012 and 2017 data on balloon undilatable lesions were available for 425 consecutive CTO PCIs in 415 patients in whom guidewire crossing was successful: 52 of 425 CTOs were balloon undilatable (12%). Mean patient age was 65 ± 10 years and most patients were men (84%). Patients with balloon undilatable CTOs were more likely to be diabetic (67 vs. 41%, P< 0.001) and have heart failure (44 vs. 28%, P= 0.027). Balloon undilatable CTOs were longer (40 mm [interquartile range, IQR 20-50] vs. 30 [IQR 15-40], P= 0.016), more likely to have moderate/severe calcification (87 vs. 54%, P< 0.001), and had higher J-CTO score (3.2 ± 1.1 vs. 2.5 ± 1.3, P< 0.001) and PROGRESS-CTO complications score (3.9 ± 1.7 vs. 3.1 ± 2.0, P< 0.005). They were associated with lower technical and procedural success (92 vs. 98%, P= 0.024; and 88 vs. 96%, P= 0.034, respectively) and higher risk for in-hospital major adverse events (8 vs. 2%, P= 0.008) due to higher perforation rates. The most frequent treatments for balloon undilatable CTOs were high pressure balloon inflations (64%), rotational atherectomy (31%), laser (21%), and cutting balloons (15%).


Conclusions - Balloon undilatable CTOs are common and are associated with lower success and higher complication rates.


Clinical Trial Registration - NCT02061436, Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO)


© 2018 Wiley Periodicals, Inc.